CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

Multiple Sclerosis Journal

Volumn 19, Issue 4, 2013, Pages 436-442

  Khalil, M ^a,b   Enzinger, C ^a   Langkammer, C ^a   Ropele, S ^a   Mader, A ^a   Trentini, A ^b   Vane, M L G ^b   Wallner Blazek, M ^a   Bachmaier, G ^a   Archelos, J J ^a   Koel Simmelink, M J A ^b   Blankenstein, M A ^b   Fuchs, S ^a   Fazekas, F ^a   Teunissen, C E ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Axonal damage; Biomarker; Brain atrophy; CSF; MRI; Multiple sclerosis; N acetylaspartate; Neurofilament

Indexed keywords

N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN; BRAIN SIZE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PREDICTION; TISSUE INJURY;

EID: 84877865991     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512458010     Document Type: Article

References (34)

1. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-2212.
2. Wattjes MP, Harzheim M, Lutterbey GG, et al. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28: 1517-1522. (Pubitemid 47462939)
3. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
4. Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
5. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747-754. (Pubitemid 29518136)
6. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009; 72: 1322-1329.
7. Teunissen CE, Dijkstra C and Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41. (Pubitemid 40023234)
8. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010; 220: 114-119.
9. Norgren N, Rosengren L and Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987: 25-31. (Pubitemid 37267883)
10. Jasperse B, Jakobs C, Eikelenboom MJ, et al. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol 2007; 254: 631-637. (Pubitemid 46781977)
11. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76: 1206-1213.
12. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-1174.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452. (Pubitemid 14237132)
14. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-1922.
15. Kester MI, Scheffer PG, Koel-Simmelink MJ, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 2012; 33: 1591-1598.
16. Lu CH, Kalmar B, Malaspina A, et al. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods 2011; 195: 143-150.
17. Petzold A, Altintas A, Andreoni L, et al. Neurofilament ELISA validation. J Immunol Methods 2010; 352: 23-31.
18. Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2) relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 1048-1054.
19. Khalil M, Enzinger C, Langkammer C, et al. Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 2011; 17: 173-180.
20. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23 Suppl 1: S208-S219. (Pubitemid 39421720)
21. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219-223. (Pubitemid 36152012)
22. Lim ET, Sellebjerg F, Jensen CV, et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005; 11: 532-536. (Pubitemid 41387697)
23. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183-198. (Pubitemid 40804835)
24. Teunissen CE and Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552-556.
25. Petzold A, Brassat D, Mas P, et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004; 10: 281-283. (Pubitemid 38807455)
26. Petzold A, Rejdak K and Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004; 75: 1178-1180. (Pubitemid 39005781)
27. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
28. Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 2010; 68: 806-815.
29. Belli A, Sen J, Petzold A, et al. Extracellular N-acetylaspartate depletion in traumatic brain injury. J Neurochem 2006; 96: 861-869.
30. Tortorella C, Ruggieri M, Di Monte E, et al. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2011; 82: 1355-1359.
31. Petzold A, Eikelenboom MI, Keir G, et al. The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 2006; 12: 325-328. (Pubitemid 43827188)
32. Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586-1590. (Pubitemid 39507573)
33. Brettschneider J, Petzold A, Junker A, et al. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006; 12: 143-148.
34. Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404. (Pubitemid 28159853)